AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05875259
Drug: BR1019-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Trial: NCT05875259
Drug: BR1019-1 + BR1019-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
Trial: NCT04807348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Chiglitazar
Trial: NCT05412576
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable
Trial: NCT06227377
Drug: QTX3034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QTX3034 will be administered at protocol defined dose
Trial: NCT06044493
Drug: Myreptic-N Tablet
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
Trial: NCT06044493
Drug: Mycophenolate mofetil Tablet/Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
Trial: NCT04354129
Drug: Cutaquig®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
Trial: NCT06085716
Drug: Open Label Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will only take placebo capsules every day.
Trial: NCT06585696
Drug: CU-20101 treatment for Moderate to Severe Glabellar Striae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36).
Trial: NCT06564207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be given twice daily for 14 days
Trial: NCT05619627
Drug: General Anesthesia (control group)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive general anesthesia for their MRI
Trial: NCT06221475
Drug: BAY2927088 coated tablet 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 coated tablets (10 mg) per single dose 30 min after a light meal
Trial: NCT06221475
Drug: [14C]-BAY2927088 solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion 15 min ending at 2 hours oral post-dose
Trial: NCT05672342
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05712044
Drug: Folic Acid 5 MG
RxNorm normalized name: folic acid 5 MG
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
Trial: NCT05738850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05438316
Drug: Tritace® tablet 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
Trial: NCT03678480
Drug: HTD1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTD1801 capsules, 250mg
Trial: NCT05133440
Drug: Radium dichloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
Trial: NCT04842201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT06561035
Drug: Opiate Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive medications in the Opiate Based arm for pain control.
Trial: NCT05538572
Drug: PRT3645
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
Trial: NCT04730206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets, identical in size and shape
Trial: NCT05726253
Drug: Supportive Care + Placebo (no antibiotics)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive oral placebo for a standard course (7 days)
Trial: NCT05025085
Drug: AGEN1777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An immunoglobulin gamma (IgG1) antibody
Trial: NCT04880577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT05286060
Drug: GX-188E, GX-I7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
Trial: NCT05580029
Drug: EMLA 5% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/10cm2 Topical 30 minutes before each fractional ablative CO2 session
Trial: NCT05125211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administrated oral spray
Trial: NCT04797663
Drug: TCA 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemical peel
Trial: NCT05393050
Drug: Methotrexate tablets
RxNorm normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is a drug used to treat rheumatoid arthritis
Trial: NCT06498128
Drug: Non-orexin receptor antagonist medications for insomnia
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
Trial: NCT06446479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06471868
Drug: IY-HCR21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betanechol 50mg
Trial: NCT06343493
Drug: Normal saline heated up to 50 °C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline heated up to 50 °C used for irrigation
Trial: NCT04854460
Drug: Revemact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 6 mg Ivermecin
Trial: NCT05498857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
Trial: NCT05216965
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Trial: NCT06081907
Drug: IBI363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
Trial: NCT06081907
Drug: IBI363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
Trial: NCT06081907
Drug: IBI363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD.
Trial: NCT06081907
Drug: IBI363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD.
Trial: NCT06081907
Drug: IBI363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
Trial: NCT00002220
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06545474
Drug: SSRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
Trial: NCT05454098
Drug: Clifutinib with fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Clifutinib with food
Trial: NCT05454098
Drug: Clifutinib with fasted state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Clifutinib without food
Trial: NCT05815303
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 po bid on day 1 to 14, every 21 day
Trial: NCT05824585
Drug: DZD8586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Trial: NCT06500091
Drug: TQB2916 injection + doxorubicin hydrochloride for injection
RxNorm normalized name: doxorubicin hydrochloride Injection
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells.
Trial: NCT05853185
Drug: Pro Root MTA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive the pulpotomy with Pro Root MTA®.
Trial: NCT01163383
Drug: 131 I-MIBG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
Trial: NCT05853185
Drug: EBRRM®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
Trial: NCT04914351
Drug: HY-0102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
Trial: NCT05337228
Drug: IN-C006 Peri inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN-C006 peri inj. will be injected continuously for 3 days.
Trial: NCT05337228
Drug: RPN301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPN301 will be injected continuously for 3 days.
Trial: NCT06415903
Drug: TQB3117 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3117 is a protein inhibitor.
Trial: NCT06108479
Drug: DF6215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (cytokine) targeting effector cells.
Trial: NCT06268015
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV every 2 weeks
Trial: NCT06268015
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
Trial: NCT04866108
Drug: fruquintinib plus capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral fruquintinib plus capecitabine
Trial: NCT06487702
Drug: fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w
Trial: NCT05459571
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05826600
Drug: OMX-0407
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation, Dose expansion
Trial: NCT05059600
Drug: ZULRESSO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ZULRESSO®.
Trial: NCT05187481
Drug: Placebo granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
Trial: NCT06419140
Drug: Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational counseling to perform nutritional, psychological, and exercise inventions
Trial: NCT06374823
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
Trial: NCT03939364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05219864
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT06037330
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
Trial: NCT06596018
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
Trial: NCT05546762
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleural irrigation with normal saline
Trial: NCT06373627
Drug: Conventional medications used for sedation-analgesia
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
Trial: NCT06373627
Drug: Medications used in addition to hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEOPA + intravenous ketamine (0.3 mg/kg)
Trial: NCT05283720
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV; Injection
Trial: NCT05283720
Drug: Doxorubicin Hydrochloride [HCl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV; Injection
Trial: NCT04335461
Drug: Regional Anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
Trial: NCT06653634
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gradual withdrawal of the medication
Trial: NCT06653634
Drug: TNF Inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of the medication
Trial: NCT04836494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BBP-671
Trial: NCT06152796
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non steroidal anti_inflammatory drug
Trial: NCT06372964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally, once daily.
Trial: NCT04834531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
Trial: NCT05087069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intravenous infusion
Trial: NCT05418504
Drug: Dental anesthesia
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dental anesthesia, used to do any dental procedure
Trial: NCT05336071
Drug: INS068 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
Trial: NCT05336071
Drug: INS068 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
Trial: NCT05144360
Drug: Atenas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
Trial: NCT05144360
Drug: Atenas placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
Trial: NCT04332588
Drug: [18F]FMISO PET/MRI imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]FMISO PET/MRI imaging
Trial: NCT04854681
Drug: TQB2928 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
Trial: NCT05021991
Drug: 100 mg PRAX-944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment with titration
Trial: NCT05021991
Drug: 60 mg PRAX-944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment with titration
Trial: NCT05021991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT05021991
Drug: Flexibly dosed 20 mg to 100 mg PRAX-944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT04931004
Drug: Mouthwash Product
RxNorm normalized name: Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.
Trial: NCT03971110
Drug: Zoladex and Casodex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
Trial: NCT05105607
Drug: D-4517.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: NCT04602754
Drug: ROSUVASTATIN CALCIUM
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg coated tablet.
Trial: NCT05216562
Drug: COVID-19 Standard Treatment
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific drugs considered standard treatment for COVID-10 by each location may vary
Trial: NCT04460235
Drug: Prevenar13 Pneumo-23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination according national guidelines
Trial: NCT05039359
Drug: FlecIH-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flecainide acetate inhalation solution
Trial: NCT04991766
Drug: [¹⁴C]-LY3484356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04991766
Drug: LY3484356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04991766
Drug: [¹⁴C]-LY3484356 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT05269394
Drug: E2814
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously in a blinded fashion
Trial: NCT05269394
Drug: Matching Placebo (E2814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously in a blinded fashion.
Trial: NCT06095765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of matching placebo once daily
Trial: NCT06222125
Drug: HB0025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB0025 IV every 2 weeks (q2w)
Trial: NCT03315832
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.